J

Janux Therapeutics Tech Stack

Clinical-stage immunotherapy platform using masking technology for tumor-targeted T cell engagers

Biotechnology Research San Diego, California 51–200 employees Founded 2017 Public Company

Janux is a public clinical-stage biotech company developing T cell engager immunotherapies, currently executing Phase 1 oncology trials and advancing IND-enabling Phase 3 programs in solid tumors. The hiring mix—dominated by director and VP-level roles across research, clinical, and biometrics—reflects a company scaling clinical operations and regulatory infrastructure. Active pain points around external partner management, pharmacovigilance vendor coordination, and trial execution efficiency suggest Janux is in the operationally complex transition from early-stage drug discovery into late-stage clinical development.

Tech Stack 12 technologies

Core StackNetSuite Python Concur Excel HPLC UPLC GraphPad Prism R Microsoft Office Adaptive Insights FlowJo PowerPoint

What Janux Therapeutics Is Building

◆Challenges

Managing external partners
Future departmental growth
Budget management and contract negotiation
Managing external pv vendors
Ensuring compliance with global pv regulations
Integrating safety into clinical development
Process improvements to enhance efficiency and accuracy
Ensuring timely trial execution
Recruiting top-tier talent
Diversity and inclusion initiatives

▲Active Projects

Phase i oncology trial execution
Study document development
Ind programs in solid tumors
Ind-enabling phase 3 clinical programs
Sop and operational tool implementation
Protocol development and regulatory submissions
Safety management plan implementation
Risk management plan development
Signal detection strategy implementation
Clinical pharmacology plans from ind through early clinical development

Hiring Activity

Steady25 roles · 9 in 30d

Department

Research

6

Finance

3

Ops

3

Executive

2

Healthcare

2

Operations

2

Clinical

1

Data

1

Seniority

Director

9

Senior

6

VP

3

Mid

2

Lead

1

Manager

1

Notable leadership hires: Biometrics Director, Pharmacovigilance Director, Clinical Pharmacology Lead, Bioinformatics Director

Company intelligence

Find more companies like Janux Therapeutics by tech stack, pain points and active projects

Get started free

About Janux Therapeutics

Janux Therapeutics is a clinical-stage immunotherapy company headquartered in San Diego, developing novel T cell engager candidates designed to generate tumor-specific immune responses while minimizing toxicity to healthy tissue. Founded in 2017 and now public, the company operates a platform based on masking technology to overcome traditional efficacy and safety limitations in the T cell engager space. Active work spans Phase 1 trial execution, IND program advancement, protocol development, and regulatory submissions across solid tumor indications. The organization is building out clinical pharmacology, biometrics, pharmacovigilance, and safety management capabilities—operational pillars required for late-stage clinical programs.

HeadquartersSan Diego, California

Company Size51–200 employees

Founded2017

Hiring MarketsUnited States

Frequently Asked Questions

What is Janux Therapeutics working on?

Janux is executing Phase 1 oncology trials and advancing IND-enabling Phase 3 clinical programs in solid tumors. Current work includes protocol development, regulatory submissions, safety and risk management plans, and clinical pharmacology planning from IND through early clinical stages.